Ventaris Surgical
Develops a ureteroscopic system for complete kidney stone clearance
$30MSeries A
Role not disclosedAV
Atypical Ventures
Activity from announced rounds
Activity in this selectionJan 31, 2026 · Jan 1, 2026
Atypical Ventures is Christopher Wake’s investment firm, associated with frontier-technology investing.
Recorded funding activity
Its recorded financings include Shennon Biotechnologies’ precision T-cell engagers for solid tumors, PhoenixAI’s analytical database for agents querying enterprise data, and Ventaris Surgical’s ureteroscopic system for kidney-stone clearance. The companies’ own announcements identify Atypical Ventures across these different technologies.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $30M 1 disclosed · full round size, not this investor’s share